Overactive Bladder - Results from #2040

REVIEW UroToday

Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool - Abstract November 9, 2012

Botulinum toxin in neurogenic detrusor overactivity - Abstract November 7, 2012

Weak detrusor contractility correlates with motor disorders in Parkinson's disease - Abstract November 6, 2012

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline - Abstract November 5, 2012

Clinical usefulness of ultrasound assessment of detrusor wall thickness in patients with neurogenic lower urinary tract dysfunction due to spinal cord injury: Urodynamics made easy? - Abstract November 3, 2012

Relationship between body mass index and overactive bladder in women and correlations with urodynamic evaluation - Abstract November 3, 2012

Male lower urinary tract symptoms associated with overactive bladder - Abstract November 2, 2012

Acute spinal cord injury: Do ambulatory patients need urodynamic investigations? - Abstract October 31, 2012

Population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist, imidafenacin - Abstract October 31, 2012

Results of a randomized phase III trial of mirabegron in patients with overactive bladder - Abstract October 30, 2012

Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder - Abstract October 29, 2012

Urgent-SQ implant in treatment of overactive bladder syndrome: 9-Year follow-up study - Abstract October 27, 2012

Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability - Abstract October 26, 2012

American Urological Association issues 4 new clinical practice guidelines October 24, 2012

Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes - Abstract October 24, 2012

ICS 2012 - OAB: Who does the definition serve best? - Slide Presentation October 24, 2012

Pharmacokinetic properties of mirabegron, a β(3)-adrenoceptor agonist: Results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women - Abstract October 23, 2012

Decreased intravesical ATP in patients with refractory detrusor overactivity and bacteriuria - Abstract October 23, 2012

MYRBETRIQ™ (mirabegron), overactive bladder treatment from Astellas, now available through U.S. pharmacies October 22, 2012

Intravesical botulinum type-A toxin (Dysport(®)) in the treatment of idiopathic detrusor overactivity in children - Abstract October 19, 2012

Page 103 of 121